Pazgan-Simon Monika, Szymanek-Pasternal Anna, Górka-Dynysiewicz Joanna, Nowicka Anna, Simon Krzysztof, Grzebyk Ewa, Kukla Michał
Department of Infectious Disease and Hepatology, Regional Specialistic Hospital, Wrocław, Poland.
Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Poland.
Arch Med Sci. 2024 Oct 22;20(5):1504-1510. doi: 10.5114/aoms/176674. eCollection 2024.
The aim of the study was to evaluate chemerin levels as a potentially useful marker in diagnosing early-stage hepatocellular carcinoma (HCC) as well as in HCC staging.
The cohort comprised 76 patients: 45 people with cirrhosis and HCC (including 13 with a single HCC lesion in the liver and 32 with metastatic lesions/spread of HCC in the liver) and 21 people with isolated cirrhosis. The control group included 10 clinically healthy people.
The degree of liver failure in the whole cohort was assessed using the Child-Turcotte-Pugh (CTP) score (class A - 34, class B - 28, class C - 4) and using the MELD score (≤ 12 points - 45 and > 12 points - 21 people). Serum chemerin level in patients with liver cirrhosis only was 53.30 ng/ml, in patients with a single HCC lesion 77.01 ng/ml, and in patients with disseminated HCC 83.58 ng/ml. In the control group, the chemerin level was 82.20 μg/ml. When patients with cirrhosis and with/without HCC were divided according to their CTP scores, the level of chemerin was as follows: class A - 83.90 μg/ml, class B - 61 μg/ml, class C - 30.10 μg/ml. For MELD scores ≤ and > 12 it was 75 μg/ml and 58 μg/ml, respectively. For BCLC staging the results were as follows: A - 20.10 μg/ml, B - 20.20 μg/ml, C -19.44 μg/ml.
Chemerin increases with the number of neoplastic lesions and decreases with the progression of liver failure as assessed using the CTP score.
本研究的目的是评估chemerin水平作为诊断早期肝细胞癌（HCC）以及HCC分期的潜在有用标志物。
该队列包括76例患者：45例肝硬化合并HCC患者（包括13例肝脏单个HCC病灶患者和32例肝脏HCC转移病灶/扩散患者）以及21例单纯肝硬化患者。对照组包括10例临床健康者。
使用Child-Turcotte-Pugh（CTP）评分（A类 - 34例，B类 - 28例，C类 - 4例）和终末期肝病模型（MELD）评分（≤12分 - 45例，>12分 - 21例）评估整个队列的肝衰竭程度。单纯肝硬化患者的血清chemerin水平为53.30 ng/ml，单个HCC病灶患者为77.01 ng/ml，播散性HCC患者为83.58 ng/ml。对照组的chemerin水平为82.20 μg/ml。根据CTP评分将肝硬化合并或不合并HCC的患者分组后，chemerin水平如下：A类 - 83.90 μg/ml，B类 - 61 μg/ml，C类 - 30.10 μg/ml。对于MELD评分≤12分和>12分的患者，分别为75 μg/ml和58 μg/ml。对于巴塞罗那临床肝癌（BCLC）分期，结果如下：A期 - 20.10 μg/ml，B期 - 20.20 μg/ml，C期 - 19.44 μg/ml。
chemerin随着肿瘤病灶数量的增加而升高，并随着使用CTP评分评估的肝衰竭进展而降低。
